Trieu Vuong
SEC insider (Form 3/4/5 filer). CIK 0001587074. CHAIRMAN AND CEO at Oncotelic Therapeutics, Inc. (OTLC). 16 reported Form 4/5 transactions since Sep 2024; latest on Jul 10, 2026. Located in AGOURA HILLS, CA.
Companies Trieu Vuong has filed insider reports for
- Oncotelic Therapeutics, Inc. (OTLC): Director, Officer, 10% Owner, CHAIRMAN AND CEO
Trieu Vuong
CIK: 0001587074
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Oncotelic Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (16 total)
- Jul 10, 2026OTLC
Oncotelic Therapeutics, Inc.
AwardDirectRestricted stock Units
2K shares- - Jul 1, 2026OTLC
Oncotelic Therapeutics, Inc.
PurchaseDirect240K shares at avg. $0.04$10K - Jun 24, 2026OTLC
Oncotelic Therapeutics, Inc.
PurchaseDirect115K shares at avg. $0.04$5K - Jun 23, 2026OTLC
Oncotelic Therapeutics, Inc.
PurchaseDirect75K shares at avg. $0.04$3K - Jun 22, 2026OTLC
Oncotelic Therapeutics, Inc.
PurchaseDirect65K shares at avg. $0.04$3K - Jun 17, 2026OTLC
Oncotelic Therapeutics, Inc.
PurchaseDirect239.8K shares at avg. $0.04$11K - Jun 15, 2026OTLC
Oncotelic Therapeutics, Inc.
PurchaseDirect96K shares at avg. $0.04$4K - Jan 22, 2026OTLC
Oncotelic Therapeutics, Inc.
AwardDirectSeries A Convertible Preferred Stock
4.4K shares- - Nov 17, 2025OTLC
Oncotelic Therapeutics, Inc.
AwardDirectSeries A Convertible Preferred Stock
4.1K shares- - Jul 10, 2025OTLC
Oncotelic Therapeutics, Inc.
PurchaseDirect104K shares at avg. $0.01$520
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jul 10, 2026 | OTLC Oncotelic Therapeutics, Inc. | Award Restricted stock Units | 2,000 | - | - | Direct |
| Jul 1, 2026 | OTLC Oncotelic Therapeutics, Inc. | Purchase | 240,000 | $0.04 | $10,344 | Direct |
| Jun 24, 2026 | OTLC Oncotelic Therapeutics, Inc. | Purchase | 115,000 | $0.04 | $5,175 | Direct |
| Jun 23, 2026 | OTLC Oncotelic Therapeutics, Inc. | Purchase | 75,000 | $0.04 | $3,375 | Direct |
| Jun 22, 2026 | OTLC Oncotelic Therapeutics, Inc. | Purchase | 65,000 | $0.04 | $2,925 | Direct |
| Jun 17, 2026 | OTLC Oncotelic Therapeutics, Inc. | Purchase | 239,759 | $0.04 | $10,693 | Direct |
| Jun 15, 2026 | OTLC Oncotelic Therapeutics, Inc. | Purchase | 96,000 | $0.04 | $4,320 | Direct |
| Jan 22, 2026 | OTLC Oncotelic Therapeutics, Inc. | Award Series A Convertible Preferred Stock | 4,426 | - | - | Direct |
| Nov 17, 2025 | OTLC Oncotelic Therapeutics, Inc. | Award Series A Convertible Preferred Stock | 4,065 | - | - | Direct |
| Jul 10, 2025 | OTLC Oncotelic Therapeutics, Inc. | Purchase | 104,000 | $0.01 | $520 | Direct |
1-10 of 16 transactions